Search Results - "Walker, Paul R."

Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review by Lecoultre, Marc, Dutoit, Valérie, Walker, Paul R

“…Tumor-associated macrophage (TAM) phagocytic activity is emerging as a new mechanism to harness for cancer treatment. Currently, many approaches are…”
Get full text

Glioma-Derived Extracellular Vesicles – Far More Than Local Mediators by Tankov, Stoyan, Walker, Paul R.

“…Extracellular vesicle (EV) secretion is a ubiquitous cellular process with both physiologic and pathologic consequences. EVs are small lipid bilayer vesicles…”
Get full text

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models by Genoud, Vassilis, Marinari, Eliana, Nikolaev, Sergey I, Castle, John C, Bukur, Valesca, Dietrich, Pierre-Yves, Okada, Hideho, Walker, Paul R

“…Immune checkpoint blockade (ICB) is currently evaluated in patients with glioblastoma (GBM), based on encouraging clinical data in other cancers, and results…”
Get full text

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients by Migliorini, Denis, Dutoit, Valérie, Allard, Mathilde, Grandjean Hallez, Nicole, Marinari, Eliana, Widmer, Valérie, Philippin, Géraldine, Corlazzoli, Francesca, Gustave, Robin, Kreutzfeldt, Mario, Blazek, Nathalie, Wasem, Joëlle, Hottinger, Andreas, Koka, Avinash, Momjian, Shahan, Lobrinus, Alexander, Merkler, Doron, Vargas, Maria-Isabel, Walker, Paul R, Patrikidou, Anna, Dietrich, Pierre-Yves

“…Abstract Background Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface…”
Get full text

Harnessing Microglia and Macrophages for the Treatment of Glioblastoma by Prionisti, Ioanna, Bühler, Léo H, Walker, Paul R, Jolivet, Renaud B

“…Glioblastoma multiforme (GBM) is the most malignant form of brain tumors, with a dismal prognosis. During the course of the disease, microglia and macrophages…”
Get full text

Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages by Tankov, Stoyan, Petrovic, Marija, Lecoultre, Marc, Espinoza, Felipe, El-Harane, Nadia, Bes, Viviane, Chliate, Sylvie, Bedoya, Darel Martinez, Jordan, Olivier, Borchard, Gerrit, Migliorini, Denis, Dutoit, Valérie, Walker, Paul R

“…Solid tumors such as glioblastoma (GBM) exhibit hypoxic zones that are associated with poor prognosis and immunosuppression through multiple cell intrinsic…”
Get full text

ER–mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem‐like cells by Bassoy, Esen Yonca, Kasahara, Atsuko, Chiusolo, Valentina, Jacquemin, Guillaume, Boydell, Emma, Zamorano, Sebastian, Riccadonna, Cristina, Pellegatta, Serena, Hulo, Nicolas, Dutoit, Valérie, Derouazi, Madiha, Dietrich, Pierre Yves, Walker, Paul R, Martinvalet, Denis

“…Glioblastoma is a highly heterogeneous aggressive primary brain tumor, with the glioma stem‐like cells (GSC) being more sensitive to cytotoxic…”
Get full text

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review by Marie, Mona A, McCallen, Justin D, Hamedi, Zahra S, Naqash, Abdul Rafeh, Hoffman, Alexander, Atwell, Druid, Amara, Suneetha, Muzaffar, Mahvish, Walker, Paul R, Yang, Li V

“…Immunotherapy has changed the paradigm of cancer treatment, yet immune checkpoint inhibitors (ICIs) such as PD-1/PD-L1 monoclonal antibodies may cause…”
Get full text

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma by Simonds, Erin F, Lu, Edbert D, Badillo, Oscar, Karimi, Shokoufeh, Liu, Eric V, Tamaki, Whitney, Rancan, Chiara, Downey, Kira M, Stultz, Jacob, Sinha, Meenal, McHenry, Lauren K, Nasholm, Nicole M, Chuntova, Pavlina, Sundström, Anders, Genoud, Vassilis, Shahani, Shilpa A, Wang, Leo D, Brown, Christine E, Walker, Paul R, Swartling, Fredrik J, Fong, Lawrence, Okada, Hideho, Weiss, William A, Hellström, Mats

“…BackgroundGlioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy. We sought to determine to what extent this immune evasion is due to…”
Get full text

Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing by Riccadonna, Cristina, Yacoub Maroun, Céline, Vuillefroy de Silly, Romain, Boehler, Margaux, Calvo Tardón, Marta, Jueliger, Simone, Taverna, Pietro, Barba, Leticia, Marinari, Eliana, Pellegatta, Serena, Bassoy, Esen Yonca, Martinvalet, Denis, Dietrich, Pierre-Yves, Walker, Paul R

“…Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs),…”
Get full text

Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma by Bassot, Arthur, Dragic, Helena, Haddad, Sarah Al, Moindrot, Laurine, Odouard, Soline, Corlazzoli, Francesca, Marinari, Eliana, Bomane, Alexandra, Brassens, Augustin, Marteyn, Antoine, Hibaoui, Youssef, Petty, Tom J., Chalabi-Dchar, Mounira, Larrouquere, Louis, Zdobnov, Evgeny M., Legrand, Noémie, Tamburini, Jérôme, Lincet, Hubert, Castets, Marie, Yebra, Mayra, Migliorini, Denis, Dutoit, Valérie, Walker, Paul R., Preynat-Seauve, Olivier, Dietrich, Pierre-Yves, Cosset, Érika

“…Glioblastoma (GBM) is a deadly and the most common primary brain tumor in adults. Due to their regulation of a high number of mRNA transcripts, microRNAs…”
Get full text

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy by Son, Christine, Moey, Melissa Y Y, Walker, Paul R, Naqash, Abdul R, Peach, Matthew Sean, Ju, Andrew W

“…Immune checkpoint inhibitors (ICIs) are used to treat locally-advanced and metastatic lung cancer, which can lead to severe immunogenic-related…”
Get full text

Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants by Belnoue, Elodie, Di Berardino-Besson, Wilma, Gaertner, Hubert, Carboni, Susanna, Dunand-Sauthier, Isabelle, Cerini, Fabrice, Suso-Inderberg, Else-Marit, Wälchli, Sébastien, König, Stéphane, Salazar, Andres M, Hartley, Oliver, Dietrich, Pierre-Yves, Walker, Paul R, Derouazi, Madiha

“…Cell penetrating peptides (CPPs) from the protein ZEBRA are promising candidates to exploit in therapeutic cancer vaccines, since they can transport antigenic…”
Get full text

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma by Dutoit, Valérie, Migliorini, Denis, Ranzanici, Giulia, Marinari, Eliana, Widmer, Valérie, Lobrinus, Johannes Alexander, Momjian, Shahan, Costello, Joseph, Walker, Paul R., Okada, Hideho, Weinschenk, Toni, Herold-Mende, Christel, Dietrich, Pierre-Yves

“…Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context…”
Get full text

Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors by Petrovic, Marija, Porcello, Alexandre, Tankov, Stoyan, Majchrzak, Oliwia, Kiening, Martin, Laingoniaina, Annick Clara, Jbilou, Tayeb, Walker, Paul R., Borchard, Gerrit, Jordan, Olivier

“…Anti-tumor responses can be achieved via the stimulation of the immune system, a therapeutic approach called cancer immunotherapy. Many solid tumor types are…”
Get full text

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer by Naqash, Abdul Rafeh, McCallen, Justin D, Mi, Emma, Iivanainen, Sanna, Marie, Mona A, Gramenitskaya, Daria, Clark, James, Koivunen, Jussi Pekka, Macherla, Shravanti, Jonnalagadda, Sweta, Polsani, Shanker, Jiwani, Rahim Ali, Hafiz, Maida, Muzaffar, Mahvish, Brunetti, Leonardo, Stroud, Chipman R G, Walker, Paul R, Wang, Kun, Chung, Youngmin, Ruppin, Eytan, Lee, Se-Hoon, Yang, Li V, Pinato, David J, Lee, Joo Sang, Cortellini, Alessio

“…BackgroundSystemic immune activation, hallmarked by C-reactive protein (CRP) and interleukin-6 (IL-6), can modulate antitumor immune responses. In this study,…”
Get full text

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition by Naqash, Abdul Rafeh, Appah, Ebenezer, Yang, Li V, Muzaffar, Mahvish, Marie, Mona A, Mccallen, Justin D, Macherla, Shravanti, Liles, Darla, Walker, Paul R

“…Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related…”
Get full text

Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours by Hoepner, Sabine, Loh, Jacelyn M S, Riccadonna, Cristina, Derouazi, Madiha, Maroun, Céline Yacoub, Dietrich, Pierre-Yves, Walker, Paul R

“…The feasibility of cancer immunotherapy mediated by T lymphocytes is now a clinical reality. Indeed, many tumour associated antigens have been identified for…”
Get full text

Local Radiotherapy Intensification for Locally Advanced Non-small-cell Lung Cancer – A Call to Arms by Kalman, Noah S., MD, MBA, Weiss, Elisabeth, MD, Walker, Paul R., MD, Rosenman, Julian G., MD, PhD

“…Abstract Chemoradiotherapy, the standard of care for locally advanced non-small-cell lung cancer (NSCLC), often fails to eradicate all known disease. Despite…”
Get full text

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) by Genoud, Vassilis, Espinoza, Felipe I, Marinari, Eliana, Rochemont, Viviane, Dietrich, Pierre-Yves, McSheehy, Paul, Bachmann, Felix, Lane, Heidi A, Walker, Paul R

“…Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact. We…”
Get full text